Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STIMATE (NEEDS NO REFRIGERATION) vs DDAVP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that increases cyclic AMP levels in renal collecting duct cells, enhancing water reabsorption and concentrating urine. It also raises plasma levels of von Willebrand factor and factor VIII by stimulating release from endothelial stores.
Synthetic analog of vasopressin; primarily activates V2 receptors in renal collecting ducts, increasing water reabsorption and concentrating urine.
Central diabetes insipidus (approved by FDA),Primary nocturnal enuresis (approved by FDA),Hemophilia A with factor VIII deficiency (off-label),von Willebrand disease (type I, some type II and III) (off-label),Nocturia in multiple sclerosis (off-label),Uremic bleeding (off-label)
Central diabetes insipidus,Nocturnal enuresis,Hemophilia A,von Willebrand disease (type I)
Intranasal: 1 spray (1.5 mg) into one nostril; may repeat once after 30-60 minutes if needed. Not to exceed 2 doses per bleeding episode.
Central diabetes insipidus: 0.1-0.4 mg orally every 12-24 hours or 0.5-1 mcg subcutaneously/intranasally every 12-24 hours. Nocturnal enuresis: 0.2-0.4 mg orally at bedtime. Hemophilia A/von Willebrand disease: 0.3 mcg/kg intravenous over 15-30 minutes or 300 mcg subcutaneously or 150 mcg intranasally (for >50 kg).
Terminal elimination half-life is 2-4 hours (mean 3 hours), which supports a dosing interval of 2-4 hours in clinical use.
Terminal elimination half-life: 2-3 hours (intravenous); 3.4-4.4 hours (oral); clinical context: antidiuretic effect persists longer (6-20 hours) due to receptor binding.
Primarily metabolized by the liver via reduction of the disulfide bridge by glutathione, and to a lesser extent by proteolysis. The metabolite is not active. Excretion: renal (filtration and tubular secretion).
Not significantly metabolized; primarily renal excretion.
Renal excretion of intact drug and metabolites accounts for >90% of elimination; biliary/fecal excretion is minimal (<5%).
Primarily renal (unchanged drug); >90% eliminated by kidneys.
Plasma protein binding is approximately 50-60%, primarily to albumin and to a lesser extent alpha-1 acid glycoprotein.
50%; binding proteins: predominantly albumin.
Volume of distribution is 0.2-0.4 L/kg, indicating moderate distribution into total body water and some tissue binding.
0.3 L/kg; indicates distribution primarily in extracellular fluid.
Intranasal: 10-20%; Intravenous: 100%; Sublingual: 5-10%; Oral: <1% (extensive first-pass metabolism).
Intranasal: 10-20%; oral: 0.1-0.5% (sublingual tablets); subcutaneous: 100% (absolute bioavailability).
No dose adjustment required for renal impairment. Insufficient data for GFR-based modifications.
Not recommended if GFR <50 m L/min; use with caution if GFR 50-90 m L/min. No standard dose adjustment available; risk of water intoxication increases in renal impairment.
No specific Child-Pugh based dose adjustments available. Use with caution in severe hepatic impairment.
No dose adjustment recommended based on Child-Pugh class. Use with caution in severe hepatic impairment due to potential for fluid overload.
Intranasal: <50 kg: 1 spray (1.5 mg) into one nostril; ≥50 kg: same as adult. May repeat once after 30-60 minutes.
Central diabetes insipidus: 0.05-0.1 mg orally every 12-24 hours (titrate). Nocturnal enuresis: 0.2-0.4 mg orally at bedtime (age ≥6 years). Hemophilia A/v WD: 0.3 mcg/kg intravenous over 15-30 minutes; intranasal dose: 150 mcg (if ≤50 kg) or 300 mcg (if >50 kg); subcutaneous: 0.3 mcg/kg.
No specific dose adjustment recommended. Monitor for adverse effects due to potential comorbidities and concomitant medications.
Start at lower end of dosing range (e.g., 0.1 mg orally once daily). Monitor serum sodium and fluid balance closely due to increased risk of hyponatremia and renal impairment.
WARNING: HYPONATREMIA and SEIZURES. Desmopressin can cause severe hyponatremia, which may be life-threatening if not promptly treated. Seizures have been reported. Risk is increased in patients with fluid or electrolyte imbalances, cystic fibrosis, heart failure, or those on medications that increase hyponatremia risk.
None
Hyponatremia and seizures: monitor serum sodium in patients at high risk; avoid excessive fluid intake.,Cardiovascular: caution in patients with coronary artery disease or hypertension, as increased blood pressure or ischemia may occur.,Fluid retention: avoid in patients with conditions predisposing to fluid overload (e.g., heart failure).,Thrombotic events: use cautiously in patients with risk factors for thrombosis (e.g., advanced atherosclerosis, smoking, oral contraceptives).,Renal impairment: dose reduction may be necessary; monitor renal function.,Cystic fibrosis: increased risk of hyponatremia and seizures.,Hypersensitivity: anaphylactic reactions reported; discontinue if allergic reaction occurs.
Risk of hyponatremia,Fluid intake restriction to avoid water intoxication,Seizures in severe hyponatremia,Cardiovascular disease caution (hypertension, coronary artery disease)
Hypersensitivity to desmopressin or any component of the formulation,Moderate to severe renal impairment (creatinine clearance <50 m L/min),Hyponatremia or history of hyponatremia,Primary nocturnal enuresis in patients with polydipsia or excessive fluid intake,Uncontrolled hypertension,Coronary artery disease of any cause,Thrombotic states (e.g., deep vein thrombosis, pulmonary embolism),Patients on medications that increase hyponatremia risk (e.g., SSRIs, NSAIDs, diuretics) unless closely monitored
Hypersensitivity to desmopressin or components,Moderate to severe renal impairment (Cr Cl < 50 m L/min),Type IIB or platelet-type von Willebrand disease,Severe hyponatremia
Avoid high-sodium foods that may increase thirst and fluid intake. Grapefruit juice may increase desmopressin absorption (monitor for enhanced effect). No other significant food interactions.
Avoid excessive water intake while on DDAVP. Do not consume grapefruit or grapefruit juice, as it may affect drug metabolism. Limit caffeine intake due to diuretic effects that could counteract DDAVP. Avoid high-sodium foods that may increase thirst and fluid intake.
Desmopressin is a synthetic analog of vasopressin. Available data in pregnant women are insufficient to determine drug-associated risk of major birth defects and miscarriage. In animal studies, no teratogenic effects were observed at doses up to 100 times the human dose. Desmopressin does not cross the placenta in significant amounts due to its large molecular weight and enzymatic degradation. During the first trimester, theoretical risk of hyponatremia and seizures in the fetus if maternal hyponatremia occurs. In the second and third trimesters, increased uterine contractility has been reported in some cases. Overall, desmopressin is considered low risk, but caution is advised.
Category B: No evidence of teratogenicity in animal studies. Insufficient human data for first trimester; risk cannot be excluded. Second and third trimester: No reported fetal harm, but avoid in preeclampsia due to antidiuretic effect.
Desmopressin is excreted into human breast milk in very small amounts. The milk-to-plasma (M/P) ratio is not well established but is estimated to be less than 0.1 based on available data. At therapeutic doses, it is unlikely to affect the nursing infant. However, caution is recommended due to potential for water retention and hyponatremia in the infant. Use only if clearly needed.
Excreted in breast milk in low amounts (M/P ratio unknown). No adverse effects reported in infants; consider risk-benefit for maternal indication.
No standard dose adjustments for pregnancy are required. However, increased clearance of desmopressin during pregnancy may necessitate dose titration based on clinical response and serum sodium levels. For central diabetes insipidus, doses may need to be increased in the second and third trimesters. Close monitoring is essential.
Volume expansion and increased renal clearance in pregnancy may require dose adjustment; no standard guidelines. For diabetes insipidus, monitor urine output and serum sodium to titrate dose. Avoid in preeclampsia.
Stimate (desmopressin acetate) is a synthetic analog of vasopressin used for diabetes insipidus and hemophilia A/von Willebrand disease. It causes vasoconstriction and platelet aggregation; monitor for hyponatremia, especially in elderly or patients with fluid intake >2 L/day. Avoid in patients with severe renal impairment (e GFR <50 m L/min). For nocturnal enuresis, restrict fluid 1 hour before and 8 hours after dose. Needs no refrigeration, but store at room temperature (15-30°C).
DDAVP (desmopressin) is a synthetic analog of vasopressin with selective V2 receptor activity, minimizing vasoconstrictor effects. Administer intranasally for central diabetes insipidus; IV for hemophilia A and von Willebrand disease (type I). Monitor serum sodium closely, especially in elderly and young children, due to risk of hyponatremia and water intoxication. Avoid in patients with habitual psychogenic polydipsia. Can be used for nocturnal enuresis, but restrict fluid intake 1 hour before and 8 hours after dose to prevent hyponatremia.
Do not refrigerate; store at room temperature.,Limit fluid intake for 8 hours after dosing to prevent water intoxication.,Report headache, nausea, confusion, or rapid weight gain (signs of hyponatremia).,If used for bedwetting, take last dose at bedtime and empty bladder before sleep.,Do not use with alcohol or other vasopressin analogs without doctor approval.
Take DDAVP exactly as prescribed; do not increase dose without consulting your doctor.,Limit fluid intake while using DDAVP to avoid severe low sodium levels (hyponatremia).,Monitor for symptoms of hyponatremia: headache, nausea, vomiting, confusion, lethargy, muscle cramps.,For nasal spray, do not blow nose for 30 minutes after administration.,Report any weight gain, persistent headache, or change in urination pattern to your healthcare provider.,Do not drink alcohol, as it may increase the risk of hyponatremia.,Store at room temperature; protect from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STIMATE (NEEDS NO REFRIGERATION) vs DDAVP, answered by our medical review team.
STIMATE (NEEDS NO REFRIGERATION) is a Antidiuretic Hormone Analog that works by Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that increases cyclic AMP levels in renal collecting duct cells, enhancing water reabsorption and concentrating urine. It also raises plasma levels of von Willebrand factor and factor VIII by stimulating release from endothelial stores.. DDAVP is a Antidiuretic Hormone Analog that works by Synthetic analog of vasopressin; primarily activates V2 receptors in renal collecting ducts, increasing water reabsorption and concentrating urine.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STIMATE (NEEDS NO REFRIGERATION) and DDAVP depend on the specific clinical indication. These are both Antidiuretic Hormone Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STIMATE (NEEDS NO REFRIGERATION) is: Intranasal: 1 spray (1.5 mg) into one nostril; may repeat once after 30-60 minutes if needed. Not to exceed 2 doses per bleeding episode.. The standard adult dose of DDAVP is: Central diabetes insipidus: 0.1-0.4 mg orally every 12-24 hours or 0.5-1 mcg subcutaneously/intranasally every 12-24 hours. Nocturnal enuresis: 0.2-0.4 mg orally at bedtime. Hemophilia A/von Willebrand disease: 0.3 mcg/kg intravenous over 15-30 minutes or 300 mcg subcutaneously or 150 mcg intranasally (for >50 kg).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STIMATE (NEEDS NO REFRIGERATION) and DDAVP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STIMATE (NEEDS NO REFRIGERATION) is classified as Category C. Desmopressin is a synthetic analog of vasopressin. Available data in pregnant women are insufficient to determine drug-associated risk of major birth defects and miscarriage. In an. DDAVP is classified as Category C. Category B: No evidence of teratogenicity in animal studies. Insufficient human data for first trimester; risk cannot be excluded. Second and third trimester: No reported fetal har. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.